It has been reported in diabetes special issue of The Lancet that the researchers have demonstrated that early intensive insulin therapy may improve the functions of insulin generating ?-cells in the patients with type-2 diabetes. The schedule of the therapy has also been linked with blood glucose control recovery and restoration.

Type-2 diabetes is considered a disorder related to metabolism which typifies by insulin resistance .Many studies that have been conducted before have recommended that there is an ability in intensive insulin therapy to alter or at least slow down the development of the disease. Professor Jianping Weng of Hospital of Sun Yat-Sen University, Guangzhou, China and co researchers tried to find the true nature of these claims.

A randomly controlled trial was conducted by the researchers at nine different centers in china in which there were 382 patients with type2 diabetes that aged 25 to 70.In this randomization process 121 patients were given standard oral diabetic medicine, continuous subcutaneous insulin infusion (CSII) which is an intensive insulin therapy was received by 137 patients while multiple daily insulin injections (MDI) was given to 124 patients. The patients stopped getting treatment after restoring the usual blood glucose control for two weeks and then the patients were followed up with diet and exercise only.

The researchers offered intravenous glucose tolerability tests and noted blood glucose; insulin and proinsulin at one year follow up before treatment and after its withdrawal.

The results, Weng and colleagues found, support the prior intensive insulin therapy. The target blood glucose control was achieved by more patients and both of insulin groups achieved it quickly than the group on oral drugs. Normoglycemia was achieved 97 % in four days in CSII group, 95% in MDI group in 5.6 days and 83.5% in the oral drug group in 9.3 days. While remission rates were 51% in CSII, 45% in MDI and 27 % in oral drug group. Similarly, function of ?-cells had also significantly improved in the patients with insulin groups.

Related links

insulin therapy

Type-2 diabetes

continuous subcutaneous insulin infusion

This article is the property ofhttp://www.allhealthsite.com
Copying and publishing any article from our site is strictly NOT allowed